Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The present study deals with the exploration of traditionally used plant (Basella rubra) against colon cancer. Aqueous leaf extract of
Basella rubra were studied for chemotherapeutic potential against chemically induced carcinogenesis model. Chemopreventive
effect of BRAE (Basella rubra aqueous extract) is evidenced by the decreased incidence and distribution of tumors along the colon with
reduction in number of ACF and AgNOR count. Immunohistochemistry findings demonstrated that BRAE significantly inhibited
the growth of cancer cells by inhibiting cell proliferation and by inducing apoptosis through activation of apoptosis pathway which
is cleared by the increased expression of apoptosis markers (p53 & Caspase-3) and decreased expression of cell proliferation markers
(PCNA & Ki67). Plants are known to be rich in a number of bioactive compounds, which have demonstrated to possess numerous
therapeutical activities. This research arose from the interest to identify the potential active anti-carcinogenic compounds and
characterize their effects on proliferation and cell death in colon cancer (HT-29) cell lines. This makes the isolation, identification of
bioactive compounds for a specific biological activity and structural determination of active compound. Bioactive compound (BR-1)
was identified by MTT assay and the compound (BR-1) was identified as flavonoid group of compound by chemical screening. Based
on the results from spectral analysis (UV, IR, MS and NMR), the active compound (BR-1) was tentatively identified as Isovitexin with
the molecular formula coined as C21H20O10. The effect of Isovitexin on the anti-proliferative and cytotoxic effects against HT-29
human colon cancer (HT-29) cells was assessed by the MTT and LDH assays. A significant decrease in cell viability and increased in
cell death was observed with increasing concentrations of Isovitexin. The results showed that IC50 of Isovitexin was found to be 21.44
�¼g/ml concentrations on HT-29 cell line. Induction of apoptosis by Isovitexin was supported with evidence of DNA fragmentation.
At the same time, apoptosis-related proteins such as Bax, Bcl-2, pro-caspase-3, and active caspase-3 expression were determined
by western blot analysis. The HT-29 cells were treated with Isovitexin for 0-24 h. An increase in expression of the Bax, which led
to an activation of caspases-3 and a decrease in expression of the anti-apoptotic factor Bcl-2 were observed in a time-dependent
manner. Isovitexin could also down-regulate the expression of pro-caspase-3 in a time-dependent manner. Our results evaluating the
molecular mechanism that Isovitexin induced apoptosis cell death in HT-29 cells may occur via caspase-3, through mitochondrial
dependent pathway. Hence, these findings support and strengthen the anticancer activity possessed by the Isovitexin and it might be
used as a good chemotherapeutic approach against colon cancer. Thus overall study reports the potential usefulness of B. rubra as a
chemopreventive agent.
Biography
Josthna Penchalaneni is currently working as an Assistant Professor at the Department of Biotechnology, Sri Padmavathi Mahila University, Tirupati, India.